Video

Dr. Hong on Comparing the Use of Sotorasib and Adagrasib in CRC

Author(s):

David S. Hong, MD

In Partnership With:

David S. Hong, MD, discusses data examining the use of sotorasib (Lumakras) and adagrasib in colorectal cancer.

David S. Hong, MD, deputy chair, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses data examining the use of sotorasib (Lumakras) and adagrasib (MRTX849) in colorectal cancer (CRC).

Both agents have appeared to generate increased response rates in CRC, Hong says. In the phase 1 CodeBreaK100 trial (NCT03600883), sotorasib demonstrated clinical activity in KRAS G12C-mutated solid tumors, including CRC. In the phase 1/2 KRYSTAL-1 trial (NCT03785249), adagrasib alone and in combination with cetuximab (Erbitux) yielded meaningful response rates in previously treated KRAS G12C-mutated CRC.

Further research will need to evaluate if these responses will lead to meaningful differences in progress-free survival and overall survival between the 2 agents, since these trials examined a small number of patients with a short follow-up, Hong explains. Notably, KRAS G12C inhibitors alone will not likely serve as tumor agnostic therapies, Hong concludes.

Related Videos
Alan Tan, MD, genitourinary oncology and melanoma specialist, Vanderbilt-Ingram Cancer Center; associate professor, medicine, Division of Hematology Oncology, Vanderbilt University Medical Center
Zosia Piotrowska, MD, MHS, instructor, Harvard Medical School; medical oncologist, Massachusetts General Hospital
Bartosz Chmielowski, MD
Raza Hoda, MD, FASCP
Armin Ghobadi, MD, professor, medicine, Oncology, Section of Bone Marrow Transplant; clinical director, Center for Gene and Cellular Immunotherapy, Siteman Cancer Center, Washington University
Timothy S. Fenske, MD, MS
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.
Craig Eckfeldt, MD
Whitney Goldsberry, MD
Related Content
FDA
January 10th 2025

Abenacianine Wins FDA Fast Track Designation for Tumor Visualization in the Lung

Jaffer A. Ajani, MD, GI medical oncologist, professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
November 14th 2024

FDA Approval Insights: Zolbetuximab for CLDN18.2+ HER2-Negative Gastric and GEJ Adenocarcinoma

FDA
January 8th 2025

Invikafusp Alfa Receives FDA Fast Track Designation for TMB-High CRC

Delve into Recent NCCN Guideline Updates for Hepatobiliary and CRC Management: With Alan P. Venook, MD
October 24th 2024

Delve into Recent NCCN Guideline Updates for Hepatobiliary and CRC Management: With Alan P. Venook, MD

OncLive’s December Roundup of Key FDA Approvals in Oncology
December 30th 2024

OncLive’s December Roundup of Key FDA Approvals in Oncology

Christopher J. Logothetis, MD, of The University of Texas MD Anderson Cancer Center
December 27th 2024

A Sense of Culture and Community Sparked a Passion in Genitourinary Oncology